Details for New Drug Application (NDA): 212215
✉ Email this page to a colleague
NDA 212215 describes TAVABOROLE, which is a drug marketed by Alembic, Amneal, Chartwell Rx, Cipla, Encube, Lupin Ltd, Padagis Us, Taro, and Zydus Lifesciences, and is included in nine NDAs. It is available from ten suppliers. Additional details are available on the TAVABOROLE profile page.
The generic ingredient in TAVABOROLE is tavaborole. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the tavaborole profile page.
The generic ingredient in TAVABOROLE is tavaborole. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the tavaborole profile page.
Summary for 212215
| Tradename: | TAVABOROLE |
| Applicant: | Taro |
| Ingredient: | tavaborole |
| Patents: | 0 |
Pharmacology for NDA: 212215
| Mechanism of Action | Protein Synthesis Inhibitors |
Suppliers and Packaging for NDA: 212215
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TAVABOROLE | tavaborole | SOLUTION;TOPICAL | 212215 | ANDA | Taro Pharmaceuticals U.S.A., Inc. | 51672-1397 | 51672-1397-9 | 1 BOTTLE, WITH APPLICATOR in 1 CARTON (51672-1397-9) / 10 mL in 1 BOTTLE, WITH APPLICATOR |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;TOPICAL | Strength | 5% | ||||
| Approval Date: | May 7, 2021 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
